U.S. Attorney’s Office for the Western District of Virginia

The U.S. Attorney’s Office for the Western District of Virginia is the federal prosecutorial institution represented in Dopesick through attorneys pursuing heroin cases in western Virginia and the federal case against Purdue Pharma. The book presents its reach across sharply different scales: investigations of regional trafficking networks and a corporate settlement over OxyContin marketing. It also places that enforcement within a broader system in which drug prosecution and treatment did not fall evenly across communities.

Federal Prosecutors and Heroin Cases

Don Wolthuis, an assistant U.S. attorney, became one of the federal government’s leading heroin prosecutors in the western half of Virginia. His account of earlier heroin use in Roanoke describes a small, largely invisible population that was commonly imagined as confined to the city’s Black community. That history changed as heroin reached suburban users and new trafficking networks connected local demand to suppliers beyond the region.

The prosecution of Clifton “Lite” Lee illustrates the scale of that change. After two suburban teenagers were caught selling heroin to friends, information on their cellphones implicated dozens more young people, many of them students at Hidden Valley High School. Prosecutors later attributed to Lee the regular importation of a thousand bags of heroin into the region, two or three times a week. He had paid $5,000 for twenty bricks, which his network sold for $30,000. Lee received an eleven-year prison sentence in 2008. The account makes the case legible not only as an individual prosecution but as evidence of a supply chain reaching into an affluent suburban community.

The Purdue Pharma Case

The office’s corporate-case work is visible in the federal prosecutors’ preparation for the case against Purdue Pharma. A prosecutors’ memo was drafted for John Brownlee, then the U.S. attorney, and later material records a Senate Judiciary Committee hearing examining the propriety and adequacy of the OxyContin criminal settlement. The sequence links internal prosecutorial deliberation to public scrutiny of the agreement rather than presenting the settlement as an uncontested endpoint.

The settlement was financially consequential: the book identifies it as the eleventh-largest fine paid by a pharmaceutical firm. Its scale gave the federal case national significance, even as the Senate hearing placed the settlement itself under examination. The episode therefore shows both the reach of federal prosecution against a drug manufacturer and the questions that remained about what such a resolution accomplished.

Enforcement in a Wider System

The book distinguishes the work of prosecuting drug cases from the broader question of how the United States responded to addiction. Its discussion of federal heroin enforcement sits alongside an account of racial disparities: Black and Hispanic people made up a disproportionate share of federal drug offenders, while doctors prescribed painkillers to people of color at much lower rates than to white patients. These observations describe the institutional setting of federal enforcement, not a specific finding about this office’s individual decisions.

That distinction matters because the narrative also describes addiction as a condition that could drive users to sell drugs or commit property crimes to avoid withdrawal, while those who supplied drugs for profit occupied a different position in the same market. Across its heroin and corporate cases, the office represents the prosecutorial arm of a system confronting both the distribution of drugs and the harms associated with them; the book’s wider account underscores that prosecution alone did not resolve the treatment and inequality questions bound up with the crisis.